The objective of the present Phase 1, dose-escalation study was to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of the dose regimens used in the FIH study in Japanese adults with advanced solid tumors (NCT03324113) expressing CEACAM5 or with elevated levels of circulating CEA. The gene discussed is CEACAM5; the disease is neoplasm.